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Abstract: We analysed the expression levels of 84 key genes involved in the regulated 
degradation of cellular protein by the ubiquitin-proteasome system in peripheral cells from 
patients with frontotemporal dementia (FTD) due to C9ORF72 and GRN mutations, as 
compared with sporadic FTD and age-matched controls. A SABiosciences PCR array was 
used to investigate the transcription profile in a discovery population consisting of  
six patients each in C9ORF72, GRN, sporadic FTD and age-matched control groups.  
A generalized down-regulation of gene expression compared with controls was observed  
in C9ORF72 expansion carriers and sporadic FTD patients. In particular, in both groups, 
four genes, UBE2I, UBE2Q1, UBE2E1 and UBE2N, were down-regulated at a statistically 
significant (p < 0.05) level. All of them encode for members of the E2 ubiquitin-conjugating 
enzyme family. In GRN mutation carriers, no statistically significant deregulation of 
ubiquitination pathway genes was observed, except for the UBE2Z gene, which displays  
E2 ubiquitin conjugating enzyme activity, and was found to be statistically significant  
up-regulated (p = 0.006). These preliminary results suggest that the proteasomal degradation 
pathway plays a role in the pathogenesis of FTD associated with TDP-43 pathology, 
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although different proteins are altered in carriers of GRN mutations as compared with 
carriers of the C9ORF72 expansion. 
Keywords: frontotemporal lobar degeneration; progranulin; C9ORF72; ubiquitination;  
E2 ubiquitin conjugating enzyme 
 
1. Introduction 
Frontotemporal lobar degeneration (FTLD) is a group of complex disorders resulting from the 
progressive deterioration of the frontal and anterior temporal lobes of the brain. The subcategories of the 
disease are defined by their dominant clinical symptom in patients; the behavioral variant frontotemporal 
dementia (FTD) that accounts for two-thirds of patients, and two language variants classified on their 
effects on fluency (Progressive non-fluent aphasia, PNFA) or semantic difficulties in communicative 
speech and understanding the semantic content of language (Semantic dementia, SD). In addition, FTD 
may overlap clinically with motor neuron disease (FTD-MND) [1]. Several genes have been identified 
as causative of autosomal dominant FTLD. In particular, microtubule associated protein tau (MAPT), 
progranulin (GRN) and chromosome 9 open reading frame (C9ORF)72 are considered the most 
important players of FTD, responsible for the majority of inherited cases. Mutations in GRN account for 
5% to 11% of cases [2,3]. Upon autopsy, GRN mutation carriers exhibit cerebral atrophy and show a 
highly constituent pattern corresponding to FTLD-TAR DNA binding protein (TDP)-43 type A, which 
is characterized by numerous short dystrophic neurites and neuronal cytoplasmatic inclusions [4]. In late 
2011, a repeated hexanucleotide in the first intron of C9ORF72 was found to be the most common 
genetic cause of amyotrophic lateral sclerosis (ALS) and FTD, with or without MND [5,6]. This 
expansion accounts for about 6% of cases [7], and is categorized histologically as a Type B pathology, 
with inclusion bodies in neurons and in glial cells that are TDP-43 positive [8]. However, Al-Sarraj  
and colleagues, described a subset of TDP-43 proteinopathy patients, carrying C9ORF72 expansion, who 
had unusual and abundant p62 positive, but TDP-43 negative inclusions in the cerebellum and 
hippocampus [9]. 
Efficient and rapid elimination of misfolded proteins is critical to the maintenance of cellular health. 
Under normal conditions, protein homeostasis is achieved through a molecular pathway called the 
ubiquitin-proteasome system (UPS) [10]. The UPS is a highly coordinated system, which regulates the 
degradation of a wide variety of proteins. Therefore, it has been supposed that dysfunction of the UPS 
is implicated in the pathogenesis of several neurodegenerative diseases, such as Huntington’s disease 
(HD) and Alzheimer’s disease (AD) [11]. Studies in animal models indicate that early impairment of the 
UPS could be considered the primary mediator of neurodegeneration, raising the possibility of 
proteostasis-based therapies to slow disease progression [12,13]. Therefore, the UPS represents, for 
mammalian cells, a major defense against misfolded proteins, particularly in post-mitotic neurons. In 
healthy conditions, proteins are marked for proteosomal degradation by covalent conjugation of 
ubiquitin (Ub), a highly conserved protein composed by 76 amino acids, in a three-step cascade. Firstly, 
the ubiquitin-activating enzyme (E1) activates Ub in an ATP-dependent reaction. Following activation, 
Ub is transferred in a second thioester linkage to one of several ubiquitn-conjugating enzymes (E2) [14]. 
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A third class of enzyme, the ubiquitin ligases (E3s), mediates the attachment of poly-ubiquitin chains to 
specific substrate proteins. Poly-ubiquitinated proteins are recognized and subsequently degraded by the 
26S proteasome [15]. Similar to other posttranslational modifications, the process of ubiquitination is 
reversible under the influence of specific de-ubiquitinating enzymes (DUBs) [16]. Both E2 and E3 
proteins exist as large families and different combinations of E2s with different E3 proteins define the 
substrate specificity. 
Another mechanism to remove misfolded protein is autophagy, the main cellular catabolic route for 
protein aggregates and damaged organelles. Autophagy plays a critical role in cytoprotection by 
preventing the accumulation of toxic proteins and acting in various aspects of immunity, including the 
elimination of invading microbes and its participation in antigen presentation. In the last decade, 
emerging evidence revealed that autophagy can distinguish and direct specific cargos to the lysosome. 
Protein degradations performed by the UPS and autophagy were regarded for a long time as 
complementary but separate mechanisms [17]. However, on the basis of recent studies, there are overlaps 
between them. The way of degradation of a misfolded, redundant, or unneeded protein may be often 
governed by the momentary activity or capacity of these systems or, in some cases, determined by strict 
regulation. Moreover, the two pathways use common adaptors capable of directing ubiquitinylated target 
proteins to both. For example, recognition of ubiquitinylated proteins during autophagy is mediated by 
ubiquitin receptors interacting with ubiquitin noncovalently, via their ubiquitin-binding domains. 
Sequestosome 1 (p62/SQSTM1), the first protein reported to have such an adaptor function [18], was 
originally discovered as a scaffold in signaling pathways regulating cell growth and proliferation. 
Recently, several rare mutations in the SQSTM1 gene, were reported in patients with FTLD and  
ALS [18–20]. Moreover, van der Zee et al., identified additional variants in SQSTM1 in FTLD patients [21]. 
Given the importance of UPS impairment in the pathogenesis of neurodegenerative diseases, in the 
present study we aimed at determining the contribution of ubiquitination pathway gene expression to the 
pathogenesis of FTLD. In particular, we analyzed the expression profile of 84 key genes involved in the 
UPS in peripheral cells from C9ORF72 and GRN mutation carriers, who are likely characterized by  
TDP-43 deposition in the brain, as compared with sporadic FTLD and age-matched controls. 
2. Results 
Gene expression profiles of 84 key genes involved in the regulated degradation of cellular proteins 
by the ubiquitin-proteasome system (Figure 1A) were performed in PBMCs from six each of: sporadic 
FTD patients, C9ORF72 expansion carriers, GRN Thr272fs (g.1977_1980delCACT) carriers, and  
age-matched healthy control groups. 
A generalized down-regulation of the gene expression profile in C9ORF72 expansion carriers and 
sporadic bvFTD patients compared with controls was observed (Figure 1B,C). In particular, in both 
groups, four genes were found statistically significant down-regulated (mean ± SD versus controls): 
UBE2N (sporadic FTD patients: −1.54 ± 1.46 fold decrease, p = 0.014; C9ORF72 expansion carriers: 
−1.2 ± 1.24 fold decrease, p = 0.011), UBE2Q1 (sporadic FTD patients: −1.48 ± 1.32 fold decrease,  
p = 0.014; C9ORF72 expansion carriers: −1.13 ± 1.12 fold decrease, p = 0.0027), UBE2E1 (sporadic 
patients: −1.94 ± 1.27 fold decrease, p = 0.002; C9ORF72 expansion carriers: −1.69 ± 1.47 fold decrease, 
p = 0.007), UBE2I (sporadic FTD patients: −1.57 ± 1.32 fold decrease, p = 0.013; C9ORF72 expansion 
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carriers: −1.42 ± 1.30 fold decrease, p = 0.011). All four genes encode for members of the E2  
ubiquitin-conjugating enzyme family. 
(A) 
 
(B) (C) 
(D) 
Figure 1. (A) Layout of the ubiquitination (ubiquitylation) pathway PCR array (PAHS-079Z). 
Heat maps of patients versus controls; (B) C9ORF72; (C) sporadic; and (D) GRN. Data are 
expressed as fold change (fold difference) and each square represents a gene of the 
ubiquitination pathway. Green indicates down-regulation, red up-regulation. 
In GRN mutation carriers, no statistically significant deregulation of ubiquitination pathway 
genes was observed, except for the UBE2Z gene, which was found to be statistically significant  
up-regulated (8.73 ± 1.06 fold increase over controls, p = 0.006, Figure 1D). Similarly to the previous 
four genes described, UBE2Z gene displays E2 ubiquitin conjugating enzyme activity. 
In addition, despite that the significant threshold was not reached, the following genes were  
up-regulated in sporadic, C9ORF72, and GRN patients versus controls, independent of the presence 
of mutations: CBL (2.79 ± 1.3, 2.5 ± 1.8, 2.81 ± 0.8 fold increase, respectively, p > 0.05), FBXO3  
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(2.48 ± 1.4, 1.97 ± 1.08, 2.10 ± 0.8, respectively, p > 0.05) and UBE2R2 (2.81 ± 1.4, 2.35 ± 1.7,  
2.98 ± 0.78, respectively, p > 0.05). 
3. Discussion 
Here, we report that genes involved in the regulated degradation of cellular proteins by the  
ubiquitin-proteasome system are deregulated in FTD. In particular, specific profiles have been found in 
carriers of GRN and C9ORF72 mutations, which are associated with TDP-43 pathology. We thus could 
hypothesize that different genetic defects (GRN or C9ORF72 mutations) converge, at some point during 
neurodegeneration, on the same pathway. 
The control of protein synthesis and turnover is essential for the health of all cells. In neurons this 
equilibrium takes on the additional importance of supporting and regulating the highly dynamic 
connections between neurons, which are necessary for cognitive functions. The UPS is able to address 
this balance thanks to the combined activity of over 500 enzymes working together to regulate  
protein-protein interaction and eliminate unwanted proteins. Evidence continues to mount for the 
necessity of UPS involvement in the dynamic remodelling of synaptic structures following synaptic 
activity [22,23], but the full role of ubiquitination pertaining to synaptic structure remains incompletely 
understood [24]. Improper clearance of proteins is believed to be a causative or contributing factor in 
many neurodegenerative diseases, which are often characterized by the accumulation of aggregated  
proteins [25]. In particular, UPS dysfunction has been reported in the most common neurodegenerative 
diseases including AD, HD and Parkinson’s Disease (PD), but little is known about the role of 
ubiquitination in the pathogenesis of FTLD. 
Our results reveal a generalized down-regulation of ubiquitination gene expression in sporadic 
patients and C9ORF72 expansion carriers. In particular, four genes UBE2I, UBE2Q1, UBE2E and 
UBE2N were down-regulated at statistically significant levels in both groups. On the contrary, no 
statistically significant deregulation of the ubiquitination gene pathway was observed in GRN mutation 
carriers, except for the UBE2Z gene, which was significantly up-regulated in GRN mutation carriers as 
compared with controls. Conversely, a few genes showed a trend towards an up-regulation all patients, 
independent of the presence of mutations, including CBL, FBXO3 and UBE2R2. However, to date, these 
genes are not very well characterized, despite being implicated in the ubiquitin ligase activity. 
UBE2I, UBE2Q1, UBE2E and UBE2N genes encodes for members of the E2 ubiquitin-conjugating 
enzyme family, but little is known about the function of this enzyme. Recently, UBE2I protein was 
associated with early events occurring in astrocytes from animal models of amyotrophic lateral  
sclerosis [26]. Moreover, the expression levels of UBE2Q1 were found down regulated in rat brain 
following traumatic brain injury [27]. Hans et al., demonstrated that UBE2E protein binds TDP-43 
directly, and identified a new potential modifier of TDP-43 neurotoxiticy [28]. Taken together these 
findings show that a modulation of ubiquitination enzymes might become useful in future preclinical 
studies, but the complete mechanism of TDP-43 turnover remains to be identified. 
In addition, it is interesting to note that the UBE2Z gene is located on chromosome 17q21, quite close 
to the GRN gene position and is widely expressed in human tissues [29]. According to Hapmap data, 
they are not however in the same linkage disequilibrium block, suggesting that mutations in GRN gene 
should not influence UBE2Z genomic structure and transcription. 
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Regarding the population studied, cases were homogeneous in terms of clinical presentation and 
phenotype and age at onset. Nevertheless, we acknowledge that our cohort is quite small and no 
neuropathological confirmation is available. This point is important especially for sporadic patients, 
because we cannot predict the pathology (TDP-43 versus tau). Therefore a replication in a larger and 
pathologically confirmed population is advisable. On the other hand, although preliminary, data we 
obtained from samples deriving from patients may help to better understand processes occurring in vivo, 
which may hopefully result in the identification of potential therapeutic targets. 
Lastly, the UPS is not alone in its handling of unwanted proteins. The autophagy system is the other 
major mechanism by which protein clearance is achieved and it may be especially important given the 
p62 pathology in C9ORF72 cases. Given that, this kind of analysis should be conducted also for 
autophagy gene expression pathway. 
4. Materials and Methods 
4.1. Patients and Controls 
Eighteen patients with FTD (six each of GRN mutation carriers, C9ORF72 expansion carriers and the 
sporadic groups) were recruited at the Alzheimer Unit of the Fondazione Cà Granda, IRCCS Ospedale 
Maggiore Policlinico, University of Milan (Milan, Italy). All patients underwent a standard battery of 
examinations, including medical history, physical and neurological examination, screening laboratory 
tests, neurocognitive evaluation and imaging. Cognitive dysfunctions were assessed by the clinical 
dementia rating (CDR), the mini mental state examination (MMSE), the frontal assessment battery 
(FAB), the Wisconsin Card Sorting Test (WCST), and the Tower of London test. The presence of 
significant vascular brain damage was excluded (Hachinski Ischemic Score < 4). The diagnosis of FTD 
was made according to current consensus criteria [30] and subsequent revisions [31,32]. 
The control group consisted of six non-demented volunteers matched for ethnic background and age, 
without memory and psycho-behavioural dysfunctions (MMSE ≥ 28). Informed consent to participate 
in this study was given by all subjects or their caregivers. Characteristics of patients and controls are 
summarized in Table 1. 
Table 1. Characteristics of frontotemporal dementia (FTD) patients and controls. 
Characteristics Sporadic C9ORF72 GRN Controls 
Number of patients 6 6 6 6 
Gender (M:F) 4:2 5:1 4:2 3:3 
Mean age (years ± SEM) 66.3 ± 8.6 63.9 ± 8.1 62 ± 9.4 65 ± 7.3 
Mean Age at onset (years ± SEM) 64.5 ± 0.44 61 ± 0.36 59 ± 0.98 – 
SEM = Standard error of mean. 
4.2. Screening of GRN and C9ORF72 Mutations 
High molecular weight DNA was isolated from whole blood using a Flexigene Kit (Qiagen, Hildren, 
Gemany). GRN sequencing was performed by direct sequencing, as previously described [33]. 
C9ORF72 genotyping was carried out by repeat-primed polymerase chain reaction and sequencing [5]. 
This method allows detection of 30 to 50 repeats; According to current literature [34], a characteristic stutter 
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amplification pattern (>40 repeats) on the electropherogram is considered evidence of a pathogenic  
repeat expansion. 
4.3. Total mRNA Isolation from Peripheral Blood Mononuclear Cells (PBMC) 
For each subject, 14 mL of blood have been collected in two BD VacutainerR CPTTM (1 mL NC,  
2 mL Ficoll) as previously described [35]. From each tube, PBMCs were separated by gradient 
centrifugation and total RNA extracted with the single step acid phenol method, using Trizol (Invitrogen, 
Carlsbad, CA, USA). RNA purity was measured by optical density and only samples with an OD 
260/280 ratio ranging from 1.8 to 2 and an OD 260/230 of 1.8 or greater were used. 
4.4. Screening of Ubiquitination Pathways by PCR Array 
RNA was retrotranscribed with RT2 First Strand Kit (SABiosciences, Frederick, MD, USA), 
according to the instruction of the manufacturer. For real time PCR experiments, the ubiquitination 
(ubiquitylation) pathway PCR array (PAHS-079Z, Figure 1) was used and runs were performed in an 
Applied BioSystems StepOne Plus system (Foster City, CA, USA). The array profiles the expression of 
84 key genes involved in the regulated degradation of cellular proteins by the ubiquitin-proteasome 
system. These arrays included also five housekeeping genes (ACTB, B2M, G3PDH, HPRT1 and RPLP0) 
for the proper normalization of the data, mRNA reverse transcription control and a positive PCR control 
(Figure 1A). 
4.5. Statistical Analysis 
The SABiosciences PCR Array data analysis was based on ΔΔCt method with normalization of  
the raw data to housekeeping genes (using the software available at http://www.sabiosciences.com/ 
pcarraydataanalysis.php). p Values were calculated based on a Student’s t-test of the replicate 2−ΔCt) 
values for each gene in the control and FTD groups. Best hits were chosen based on statistical significance 
(p < 0.05). Haploview 4.2 software was used to test for linkage disequilibrium (LD) blocks. 
5. Conclusions 
In conclusion, knowledge of the UPS components that are involved in FTD pathogenesis will be 
helpful for the identification of potential therapeutic targets, which aim to limit, at early stages, the 
accumulation of misfolded proteins without disturbance of this major proteolytic pathway. 
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